Arbutus Biopharma Corporation (ABUS) Stock

Arbutus Biopharma Corporation is a leading biopharmaceutical firm based in Warminster, Pennsylvania, focused on pioneering therapies for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses within the United States. The company's robust HBV product pipeline includes AB-729, an innovative RNA interference product candidate administered subcutaneously. This technology, utilizing novel covalently conjugated N-acetylgalactosamine (GalNAc) delivery, targets hepatocytes to inhibit viral replication and diminish various HBV antigens. Additionally, Arbutus Biopharma develops AB-836, an oral capsid inhibitor designed to suppress HBV DNA replication.

In its commitment to advancing therapeutic options, Arbutus Biopharma pursues a diverse array of research and development initiatives. Notable programs include AB-161, an oral HBV RNA destabilizer aimed at reducing HBsAg and other viral proteins, and AB-101, an oral PD-L1 inhibitor intended to reinvigorate HBV-specific immune responses. Furthermore, the company is actively engaged in the development of small molecule antiviral medications to combat coronaviruses, including COVID-19.

Arbutus Biopharma's strategic approach extends beyond internal innovation, as evidenced by its strategic alliances, licensing agreements, and research collaborations with prominent entities such as Talon Therapeutics, Gritstone Oncology, Alnylam Pharmaceuticals, and others. These partnerships enhance the company's ability to leverage cutting-edge technologies and accelerate the development of groundbreaking therapies.

Founded as Tekmira Pharmaceuticals Corporation and rebranded in July 2015, Arbutus Biopharma continues to expand its footprint in the biopharmaceutical landscape. With a steadfast commitment to scientific excellence and therapeutic advancement, the company remains dedicated to addressing significant unmet medical needs and improving patient outcomes in the realm of viral diseases.